FOLFOXIRI ± molecular targeting agent (bevacizumab or panitumumab) for conversion from unresectable to resectable in the advanced/recurrent colorectal cancer.

Authors

Kodai Takemori

Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan

Kodai Takemori , Kazuma Kobayashi , Yusuke Inoue , Satomi Okada , Toshiyuki Adachi , Akihiko Soyama , Tomohiko Adachi , Kengo Kanetaka , Susumu Eguchi

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

Poster Details

Meeting

2024 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session C: Cancers of the Colon, Rectum, and Anus

Track

Colorectal Cancer,Anal Cancer

Sub Track

Therapeutics

Citation

J Clin Oncol 42, 2024 (suppl 3; abstr 99)

DOI

10.1200/JCO.2024.42.3_suppl.99

Abstract #

Poster Bd #

Abstract Disclosures

FEATURED

FOLFOXIRI ± molecular targeting agent (bevacizumab or panitumumab) for conversion from unresectable to resectable in the advanced/recurrent colorectal cancer.

Authors

Kodai Takemori

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Poster Details

Meeting

Session Type

Session Title

Track

Sub Track

Citation

DOI

Abstract #

Poster Bd #

Similar Posters

Poster

Treatment strategies in colorectal cancer patients with initially unresectable liver-only metastases: The randomized phase III CAIRO5 study of the Dutch Colorectal Cancer Group.

Poster

Poster

PROX: Primary resistance to oxaliplatin containing regimen in the first line treatment of metastatic colorectal carcinoma—Retrospective analysis.

Poster

TRIBE-2 by GONO group: A phase III strategy study in the first- and second-line treatment of unresectable metastatic colorectal cancer (mCRC) patients.